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Human newborns and infants are bombarded with multiple pathogens on leaving the
sterile intra-uterine environment, and yet have suboptimal innate immunity and limited
immunological memory, thus leading to increased susceptibility to infections in early
life. They are thus the target age group for a host of vaccines against common bacterial
and viral pathogens. They are also the target group for many vaccines in development,
including those against tuberculosis (TB), malaria, and HIV infection. However, neonatal and
infant responses too many vaccines are suboptimal, and in the case of the polysaccharide
vaccines, it has been necessary to develop the alternative conjugated formulations in order
to induce immunity in early life. Immunoregulatory factors are an intrinsic component of
natural immunity necessary to dampen or control immune responses, with the caveat that
they may also decrease immunity to infections or lead to chronic infection. This review
explores the key immunoregulatory factors at play in early life, with a particular emphasis
on regulatory T cells (Tregs). It goes on to explore the role that Tregs play in limiting
vaccine immunogenicity, and describes animal and human studies in which Tregs have
been depleted in order to enhance vaccine responses. A deeper understanding of the role
thatTregs play in limiting or controlling vaccine-induced immunity would provide strategies
to improve vaccine immunogenicity in this critical age group. New adjuvants and drugs are
being developed that can transiently suppressTreg function, and their use as part of human
vaccination strategies against infections is becoming a real prospect for the future.
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INTRODUCTION
The infant immune system is uniquely adapted to meet the chal-
lenges of early life (Kollmann et al., 2012). The newborn emerges
from an immune-protected environment into a world where they
constantly encounter new antigens. There is therefore a need to
have a series of immunoregulatory mechanisms in place in order
to prevent excessive inﬂammation and tissue damage. At the same
time the infant needs to develop immune memory upon pathogen
encounter in order to be protected against future challenge. The
newborn has little immunological memory, and neonates and
infants are heavily reliant on innate immunity to protect them
against antigenic challenge as discussed in a series of comprehen-
sive review articles (Levy, 2007; Ghazal et al., 2013; Levy andWynn,
2014).
In this review we discuss the regulatory factors that infants
employ to suppress or control their developing immunity. We will
focus on regulatory T cells (Tregs) in particular, and the poten-
tial role they play in suppressing or controlling vaccine-induced
immunity in early life. We will explore the mechanisms of action
used by Tregs to confer suppression, and differences in the pheno-
typic and functional characteristics between Tregs in infants and
adults. We will discuss the role of Tregs in malaria, HIV, and hep-
atitis C virus (HCV) infections; and brieﬂy describe the results
of clinical trials in human infants of vaccines against these three
infections. A detailed understanding of the immunoregulatory
factors controlling vaccine immunogenicity in early life may
provide potential strategies for improving vaccine efﬁcacy in
this vulnerable age group. We will discuss immunotherapeutic
agents and vaccine adjuvants developed for use in humans that
can down-modulate Treg activity and thus enhance vaccine efﬁ-
cacy, demonstrating that this approach is a viable option for the
future.
THE INFANT IMMUNE SYSTEM
INNATE IMMUNITY
The innate immune system which acts as the ﬁrst line of defense
against infection is suboptimal at birth, and does not reach
full capacity until teenage years. Innate cells express pattern
recognition receptors (PRRs) which detect highly conserved pat-
tern associate molecular patterns (PAMPs) expressed by invading
pathogens or vaccines, including Toll-like receptors (TLRs) and
NOD-like receptors (NLRs). Newborns and young infants have
similar levels of expression of these PRRs as adults (Kollmann
et al., 2012), however, responses to PRR stimulation are low at
birth in part due to diminished innate signaling pathways such
as IRF7 translocation (Danis et al., 2008) and TLR3 and 4 signal-
ing (Aksoy et al., 2007). Reactivity to certain PRR agonists, e.g.,
TLR4 and TLR5 are acquired rapidly, and reactivity of the viral
ssRNA sensing TLR7 and TLR8 receptors is robust from birth
(Burl et al., 2011), hence TLR7/8 agonists are being investigated
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as possible adjuvants to boost immune responses to neonatal vac-
cines (Dowling et al., 2013). Th2 (IL-6, IL-10) and Th17 (IL-6,
IL-23) polarizing cytokines dominate the innate response in early
life, while TNF-α and IL-1β responses rise in the ﬁrst few years
of life as the former cytokines decline (Belderbos et al., 2009;
Kollmann et al., 2009; Nguyen et al., 2010; Burl et al., 2011).
Infant dendritic cell (DC) function is also suboptimal (De Wit
et al., 2004; Goriely et al., 2004; Aksoy et al., 2007), and NK cells
(Guilmot et al., 2011) and neutrophil functions (Carr, 2000) are
less potent than in adults. Low complement levels in neonatal
plasma are thought to increase susceptibility to certain bacte-
rial infections, and lead to impaired adaptive immunity (Levy,
2007).
ADAPTIVE IMMUNITY IN INFANCY
Infant T cell immunity
The adaptive immune system is characterized by minimal
immunological memory at birth, since the newborn has been rela-
tively protected from antigenic exposure in utero, andmost of their
T cells are of anaïvephenotype. Furthermore, high levels of TGF-β,
progesterone and prostaglandin E2 in utero required to prevent
the mother developing Th1 alloreactivity to her fetus (Philbin and
Levy, 2009), alongside poor innate Th1 support (Langrish et al.,
2002), result in the newborn having intrinsically skewed Th2-
type immunity from birth. Additionally, the Th17 biased innate
immunity in infants also results in a Th17 adaptive bias. This
bias against Th1 immunity results in an increased vulnerability
to microbial infections and suboptimal reactivity to many vac-
cines. Despite this, infants have been shown to stimulate adult level
Th1 type immune responses to BCG vaccination (Marchant et al.,
1999) and are thus capable of robust Th1 immunity. However,
neonatal BCG vaccination results in a Th17 biased mycobacte-
rial response compared to those receiving BCG at 4 12 months of
age (Burl et al., 2010), in keeping with the Th17 bias described
above.
Infant B cell immunity
Newborn infants acquire IgG antibodies transplacentally from
theirmotherswhich provide protection against infections encoun-
tered in early life, while the other immunoglobulin subclasses are
unable to cross the maternal–placenta interface. The maternally
acquired antibody (MAb) levels wane over the ﬁrst 6 months of
life and are usually absent by 1 year of age. Several studies suggest
that MAbs inhibit humoral responses to infant vaccines; including
live measles vaccine (Albrecht et al., 1977) and oral poliomyeli-
tis vaccine, and non-live vaccines including pertussis (Burstyn
et al., 1983; Englund et al., 1995), tetanus and diphtheria tox-
oids (Bjorkholm et al., 1995), Hib conjugate vaccine (Claesson
et al., 1989; Daum et al., 1991) and hepatitis A vaccine (Kanra
et al., 2000); while other studies report no inﬂuence of MAbs on
responses to these vaccines (Gans et al., 1998; Siegrist et al., 1998;
Sallusto et al., 1999). Responses may still be protective even if MAb
inhibition occurs (Jones et al., 2014), and while MAbs may inter-
fere with the generation of humoral responses to vaccination, T
cell responses do not seem to be similarly affected (Siegrist, 2003).
Human neonatal antibody responses are delayed in onset,
of shorter duration, achieve lower peak levels, and have lower
afﬁnity than adults. The isotype distribution also differs, with
IgG1 and IgG2 levels peaking at ∼3–4 years of age, and IgG4
only reaching adult levels at 4–6 years of age, while IgG3
is stable from birth (Ngamphaiboon et al., 1998). Histological
studies of infant splenic tissue show that the marginal zone
does not reach full development until 2 years of age, which
alongside low complement levels (Zandvoort and Timens, 2002;
Kruetzmann et al., 2003) and low expression of CD21 (com-
plement receptor 2; Grifﬁoen et al., 1993), would account for
the delayed antibody response to T cell independent glycopro-
teins and polysaccharide antigens, including encapsulated bacteria
such as Streptococcus pneumoniae and Haemophilus inﬂuenzae,
and thus poor reactivity to polysaccharide vaccines (Adkins et al.,
2004).
IMMUNOREGULATORY FACTORS IN NEONATAL AND INFANT
PLASMA
Neonatal and infant plasma contain a number of immunoregu-
latory factors that serve to maintain Th2 polarization, and limit
pro-inﬂammatory innate and adaptive immunity. Newborns and
infants have high levels of plasma adenosine, an endogenous
purine metabolite with immunosuppressive properties. Adeno-
sine causes mononuclear cells to produce cAMP, which acts as
a second messenger to inhibit TLR-stimulated production of
pro-inﬂammatory cytokines while polarizing toward IL-10 and
Th17 cytokine production (Levy et al., 2006; Power Coombs et al.,
2011; Philbin et al., 2012). Neonatal monocytes have increased
sensitivity to these effects of adenosine via their adenosine A3
receptors, thus modulation of this system could potentially be
used to enhance innate and therefore adaptive pro-inﬂammatory
responses.
Several studies have shown that there are high levels of the
immunosuppressive cytokine IL-10 in cord blood (CB; De Wit
et al., 2004; Belderbos et al., 2009; Nguyen et al., 2010). IL-10 can
be produced by most cell types of the immune system, including
antigen presenting cells (APCs), granulocytes, and Th1, Th2 and
many regulatory T cell subsets. IL-10 acts at a number of stages of
an immune response in order to control inﬂammation. It inhibits
the production of pro-inﬂammatory cytokines and chemokines
by monocytes, macrophages and DCs, leading to increased IL-10
production by various T cell subsets. It suppresses both Th1 and
the more recently described “Th1+Th17” cells, while enhancing
CD4+FOXP3+ (forkhead box P3) regulatory T cell survival and
activity, and promoting IgG and IgA class switching by B cells
(Banchereau et al., 2012).
HUMAN REGULATORY T CELL SUBTYPES AND THEIR MODES
OF ACTION
Regulatory T cells are unique subpopulations of T cells that play
a major role in immune homeostasis and tolerance (Sakaguchi,
2000; Belkaid et al., 2002; Mills and Mcguirk, 2004; Belkaid, 2007).
Although Tregs have been shown to be beneﬁcial in preventing
an over-exuberant response and immune pathology following
encounter with pathogens (Belkaid, 2008; Belkaid and Tarbell,
2009), they have also been shown to limit the favorable effec-
tor responses required for sterilizing immunity, thus allowing
pathogen persistence (Kao et al., 2010).
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THYMUS DERIVED AND PERIPHERAL CD4+FOXP3+ Tregs
The Treg ﬁeld was invigorated with the discovery of the transcrip-
tion factor FOXP3 which is vital for the development, function
and homeostasis of Tregs (Fontenot et al., 2003; Hori et al., 2003),
and is thus considered the master regulator of Tregs. Its impor-
tance is further highlighted by patients with mutations in FOXP3
who develop a severe fatal disorder known as immune dys-
regulation, polyendocrinopathy, enteropathy, X-linked (IPEX)
syndrome (Bennett and Ochs, 2001; Gambineri et al., 2003).
Recently a group of experts in the Treg ﬁeld introduced a con-
sensus nomenclature for FOXP3+ Tregs. They suggest replacing
previously used terms which they describe as being to some extent
“inaccurate and ambiguous” (Abbas et al., 2013). They recom-
mend that the subset of FOXP3+ Tregs of thymic origin, which
are also known as natural Tregs (nTregs), should be called thymus-
derived Tregs (tTregs); while FOXP3+ Tregs that differentiate in
the periphery should be called peripherally derived Tregs (pTreg)
rather than the previous term inducible Tregs (iTregs). The pTregs
are induced in the periphery in response to antigenic stimulation,
and possess identical characteristics to tTregs, and therefore both
subsets will be described together.
Phenotype of human CD4+FOXP3+ Tregs
CD4+FOXP3+ Tregs are themostwidely studiedTreg subset. They
were ﬁrst described as a subset of CD4+ Tcellswhich constitutively
express the interleukin 2 (IL-2) receptor alpha-chains (CD25) and
can prevent the development of autoimmunity inmice (Sakaguchi
et al., 1995).
Determining the precise phenotype of human CD4+FOXP3+
Tregs has proved difﬁcult with many conﬂicting studies.
Since CD25 is transiently expressed on conventional T cells
(Hatakeyama et al., 1989), the CD25hi subset is described as
a more reliable marker of CD4+FOXP3+ Tregs in humans
(Schmetterer et al., 2012). Human FOXP3+ Tregs also tend
to express low levels of the IL-7 receptor CD127 (Liu et al.,
2006; Seddiki et al., 2006). Therefore the most commonly ana-
lyzed phenotypes in human studies are CD4+CD25+FOXP3+
or CD4+CD25+CD127lo. Furthermore, human CD4+FOXP3+
Tregs generally express high levels of the co-inhibitory receptor
cytotoxic T lymphocyte antigen 4 (CTLA4; Sansom and Walker,
2006). More recently the chemokine markers CCR4, CCR6,
CXCR3, and CXCR10 have been proposed to deﬁne four distinct
populations of human tTregs, each with distinct functional char-
acteristics (Duhen et al., 2012). Each of these four Treg subsets
are thought to co-localize in vivo with and regulate a distinct Th
subset (Th1, Th2, Th17, Th22) expressing the same chemokine
receptors.
CD45RA expression can be used to distinguish tTregs that are
naïve or resting (rTregs; FOXP3loCD45RA+) from the memory
subset described as activated Tregs (aTregs; FOXP3hiCD45RA−;
Miyara et al., 2009). The memory Tregs can be further subdivided
into central memory (TregCM) and effector memory (TregEM)
similarly to Th cells, based on the expression of chemokine
receptor 7 (CCR7; Sallusto et al., 1999; Tosello et al., 2008).
Certain subpopulations among CD4+FOXP3+ Tregs are more
suppressive than others. For example, Tregs expressing the tumor
necrosis factor receptor 2 (TNFRII) are thought to represent
a highly suppressive CD4+FOXP3+ Treg subset (Minigo et al.,
2009). Those CD4+CD25+FOXP3+ Tregs expressing the trans-
membrane cyclic ADP ribose hydrolase CD38 (mainly thymic
derived and in the spleen) have particularly high suppressive
activity in a murine model (Patton et al., 2011). CD38 is part
of a cascade involved in the production of the immunosup-
pressive factor adenosine from NAD+ (Horenstein et al., 2013)
which can have immunoregulatory properties as discussed ear-
lier. Interestingly, the majority of infant T cells express CD38
(Scalzo-Inguanti and Plebanski, 2011), and as previously men-
tioned infants also have high plasma levels of adenosine, but a link
between these two factors has yet to be explored in neonates and
infants.
Mechanisms of CD4+FOXP3+ Treg mediated suppression
CD4+FOXP3+ Tregs can suppress the proliferation and activa-
tion of a multitude of immune cell types including T cells, NK
and NKT cells, monocytes, macrophages, B cells, DCs, and
eosinophils. They employ a variety of mechanisms to mediate
this suppression, and are thought to be ﬂexible in this respect by
adapting their mechanism according to their local environment
(reviewed by Wing and Sakaguchi, 2012). Both IL-2 and CTLA-
4-dependent mechanisms have been described, with CD25 and
CTLA-4 knockout mice having a similar phenotype to Foxp3 deﬁ-
cient mice (Wing and Sakaguchi, 2012). It is thought that the
constitutive expression of CD25 by CD4+FOXP3+ Tregs allows
them to consume the available IL-2, depriving effector T cells
(Teffs) and leading to effector cell death (De La Rosa et al., 2004).
Those tTregs expressing CTLA-4 can suppress T cell responses
via down-modulation of CD28 signaling (Walker, 2013), and
reduced co-stimulatory capacity of CD80/86 expressed by DCs
(Wing et al., 2011).
A commonly used mechanism of Treg action is the production
of soluble inhibitory factors, including either membrane bound or
released immunosuppressive cytokines IL-10, TGF-β, and IL-35
(Collison et al., 2007). FOXP3+ Tregs can also generate high con-
centrations of adenosine (Mandapathil et al., 2010) which binds to
theA2a receptor on immune cells activating an immunoinhibitory
loop (Sitkovsky and Ohta, 2005) which results in inhibition of
T cell proliferation and cytokine production (Raskovalova et al.,
2005).
TYPE 1 REGULATORY T CELLS (Tr1)
The Tr1 Tregs are a unique Treg subset that do not rely on the
expression of high levels of CD25 or FOXP3 for their function
(Levings andRoncarolo, 2000). They are activated in the periphery
following antigenic stimulation in the presence of IL-10 (Groux
et al., 1997; Vieira et al., 2004). Recently, lymphocyte-activation
gene 3 (LAG3) and CD49b have been described to represent
speciﬁc markers for Tr1 cells (Gagliani et al., 2013).
The Tr1 Tregs are known to produce high levels of the
immunosuppressive cytokines IL-10 and TGF-β, some IL-5,
low levels of IFN-γ and IL-2, and no IL-4 (Groux et al.,
1997). The secretion of IL-10 is the main mechanism by
which Tr1 cells are thought to mediate suppression. The IL-
10 can be either free or membrane bound, and has been
shown to suppress Teff proliferation/activation both directly
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and indirectly via a modulation of APC function (Roncar-
olo et al., 2006). They have also been shown to use cell–cell
contact mechanisms (Gregori et al., 2012) and the production
of granzyme B and perforin (Gregori et al., 2010) to mediate
suppression.
T HELPER TYPE 3 CELLS (Th3)
This unique subset of TGF-β producing Tregs was identiﬁed in
early studies investigating oral tolerance. They have been shown
to suppress the proliferation and activation of Th1 cells and sup-
press the development of autoimmunity in the mouse model of
multiple sclerosis (Chen et al., 1994). They become activated in
the periphery upon encounter with a speciﬁc antigen, and sup-
press via the production of the inhibitory cytokine TGF-β. Some
studies show that Th3 cells may have a role to play in control-
ling autoimmunity and allergy in humans (Andersson et al., 2002;
Perez-Machado et al., 2003), but the role that this subset plays in
themaintenance of immune tolerance in humans is still not clearly
deﬁned.
CD8+ Tregs
While CD4+ Tregs have been widely studied in humans,
CD8+ Tregs have not received the same attention. However,
there is increasing evidence that subsets of CD8+ Tregs also
play important immunoregulatory roles, and impaired CD8+
Treg function may lead to autoimmunity (Hu et al., 2004;
Lu et al., 2008). The most widely described phenotype for
CD8+ Tregs is CD25+CD28− (Ciubotariu et al., 1998; Filaci
et al., 2004). Other markers include CD122, CTLA-4, GITR,
CD38, CD103, and CD8αα (Uss et al., 2006; Simone et al.,
2008; Smith and Kumar, 2008; Liu et al., 2014); a host of
different CD8 Treg subsets have been described in humans
expressing various combinations of these markers (Suzuki et al.,
2012). While FOXP3 expression has been described in many
CD8 Treg subsets, it may also represent an activation marker
rather than acting as a regulatory factor since CD8+FOXP3+
cells have been found to be minimally suppressive in some
studies (Mayer et al., 2011). Mechanisms of action of CD8+
Tregs that have been reported include cell–cell contact medi-
ated suppression, secretion of the suppressive cytokines IL-
10 and TGF-β, and induction of APC energy (Suzuki et al.,
2008). CD8+CD45RA+CCR7+FOXP3+ cells may represent a
discrete subset of CD8 Tregs which interfere with the TCR sig-
naling cascade (Suzuki et al., 2012). More extensive work is
required to better understand the origin and role of CD8+
Tregs in immunoregulation and autoimmunity, particularly in
humans.
PHENOTYPIC AND FUNCTIONAL DIFFERENCES BETWEEN
Tregs IN INFANTS COMPARED TO ADULTS
Distinct qualitative and quantitative differences have been iden-
tiﬁed between the Tregs in adults and those of infants. Most of
the studies in infants have analyzed Tregs in neonatal CB for com-
parison with adults, and different phenotypic markers have been
used to characterize the Tregs in these studies contributing to some
discrepancies in the results.
FOXP3+ Tregs have been found in much higher levels at birth
compared to adults, whether deﬁned as CD4+CD25+CD127lo
(Nettenstrom et al., 2013) or CD4+CD25+FOXP3+ (Flanagan
et al., 2010). Preterm infants have been shown to have higher
levels still (Luciano et al., 2014). However, a study comparing
CD4+CD25+CD127lo Tregs at different age groups, showed slight
increases in Treg frequencies with age: 6.10% in CB; 7.22% in
adults aged 20–25 years; and 7.5% in adults over the age of
60 years (Santner-Nanan et al., 2008); and another study found
that neonates had similar number of cells expressing FOXP3 com-
pared to their mothers, and a lower number of CD4+CD25bright
cells (Ly et al., 2009). The reason for these conﬂicting results is not
known.
Cord blood Tregs have been shown to be predominantly
of the CD45RA+CD45RO− naïve phenotype in several studies
(Kanegane et al., 1991; Wing et al., 2002; Takahata et al., 2004; Ly
et al., 2009; Flanagan et al., 2010). Other phenotypic differences
between cord and adult Tregs include the observation that CB
Tregs are mostly CD27+ and thus at an earlier differentiation state
than their mothers; they have a lower apoptotic potential as evi-
denced by lower CD95/Fas expression than their mothers; and less
CD62L suggesting less of a TregCM lymphnode homing phenotype
(Flanagan et al., 2010). CB Tregs also express less CCR6 than their
matched mothers, which is the chemokine receptor that charac-
terizes the Th17- and Th22-like Tregs (Duhen et al., 2012). Since
infants are Th2 biased then their Tregs should be predominantly of
aCCR4+CCR6−CXCR3− Th2Treg phenotype in keepingwith the
classiﬁcation discussed previously (Duhen et al., 2012), although
this has not been investigated in infants.
In vitro Treg suppression assays are difﬁcult to perform in
infants due to the lack of availability of large volumes of blood,
combined with the low Treg frequencies in peripheral blood.
Studies using CB are easier since large volumes are available
for study. Several studies have shown that newborn CB Tregs
are highly functional whereby they suppress T cell proliferation
and IFN-γ production, further deviating from a Th1 response
(Godfrey et al., 2005; Wing et al., 2005). Fan et al. (2012) found
that CD4+CD25+ CB Tregs had a stronger immunosuppressive
function than adult blood Tregs following two cycles of polyclonal
stimulation. Mayer et al. (2012) found that CB CD4+CD25hi cells
failed to suppress upon TCR activation whereas those freshly
puriﬁed from adult blood did, but CB Tregs became strongly sup-
pressive after antigen-speciﬁc stimulation. Another study found
that low FOXP3 expression levels by CB Tregs correlated with
minimal suppressive activity, but following expansion there was
a signiﬁcant increase in the suppressive activity of these CB
Tregs with a shift from the CD45RA+ to the CD45RA− pheno-
type (Fujimaki et al., 2008). It has recently been shown that CB
Tregs can be expanded more easily than adult peripheral blood
Tregs, and CB Tregs are better suppressors in allogeneic mixed
lymphocyte reactions than their adult counterparts (Lin et al.,
2014).
Taken together these studies suggest distinct differences
between infant and adult Tregs. Overall they seem to be present
in higher frequencies than in adults, are more naïve and less dif-
ferentiated, and are highly suppressive; all supporting an active
immunoregulatory role in early life.
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THE ROLE OF Tregs IN REGULATING IMMUNITY TO
MALARIA, HIV, AND HEPATITIS C VIRUS
Regulatory T cells have been implicated with an immunoregula-
tory role in both murine and human malaria infections (Scholzen
et al., 2010). In mice, ablation of Foxp3+ Tregs led to increased
T cell activation and decreased parasitaemia (Abel et al., 2012).
In vivo depletion of Tregs protected mice from experimental
cerebral malaria in a Plasmodium berghei model of infection
(Wu et al., 2010). A FOXP3 promoter polymorphism in children
has been associated with signiﬁcant parasitaemia in a Con-
golese study suggesting a Treg role (Koukouikila-Koussounda
et al., 2013). Malaria infected red blood cells (iRBCs) induced
CD4+CD25hiFOXP3+ Tregs in vitro in healthy human volunteers
(Scholzen et al., 2009). In human malaria sporozoite challenge
experiments, Tregs have been shown to be induced rapidly after
infection, and linked to lower pro-inﬂammatory cytokines and
increased TGF-β production (Walther et al., 2005). Another study
showed that malaria antigens can activate latent TGF-β on the
surface of aTregs (Clemente et al., 2011). A study of 112 sub-
jects in Kenya (infants to adults) found a correlation between the
frequency of CD4+CD25hi T cells and increased risk of clinical
malaria, suggesting Tregs may negatively affect natural immunity
to malaria in humans (Todryk et al., 2008). In naturally exposed
Gambians CD4+FOXP3+CD127lo Tregs during acute infection
were inversely correlated with memory responses at 28 days, sug-
gesting suppression of immune memory. In the same study, a
CD4+FOXP3−CD45RO+ T cell population co-producing IFN-γ
and IL-10 was more prevalent among children with uncompli-
catedmalaria than thosewith severe disease, suggesting a beneﬁcial
immunoregulatory role for this IL-10 producing subset, presum-
ably by limiting excessive inﬂammation (Walther et al., 2009). A
role for the highly suppressive TNFRII+ Tregs in malaria para-
site survival has been implicated in a study of Indonesian school
children (Wammes et al., 2013). Overall, these data support an
induction of Tregs during acute malaria infection which can
limit the generation of immune memory and increase suscepti-
bility to infection, but also control immunopathology and disease
severity.
The role of Tregs in HIV infection remains poorly understood
and the data are conﬂicting, in part due to the different pheno-
types used to deﬁne Tregs in the various studies. However, the
studies do support a regulatory role. For example, combination
anti-retroviral therapy (cART) non-responders with persistent
CD4 counts <200 cells/μL on therapy had higher peripheral
blood Tregs and aTregs than cART responders, with higher IL-
10+ Tregs and lower FOXP3 in lymphoid tissue (Gaardbo et al.,
2014). Another longitudinal study also found higher numbers
of Tregs associated with immunological non-responders deﬁned
as CD4 <500/μL (Saison et al., 2014). A study analyzing multi-
ple Treg phenotypes in HIV infected individuals found evidence
of Treg redistribution depending on HIV status (Serana et al.,
2014). Untreated viraemic patients with stable CD4 counts had
higher proportions of naïve Tregs with decreased TregCM com-
pared to those on cART and healthy controls (Serana et al.,
2014). The study suggests that effective cART restores Treg
homeostasis since Treg subpopulations in the cART group were
similar to those of healthy donors. Increased proportions and
decreased numbers of Tregs associate with progression of HIV
(Wang et al., 2013). Treg depletion in a murine chronic retro-
virus infection model resulted in reduced viral loads (Dietze et al.,
2013). In combination, the data suggest that Tregs may suppress
HIV-speciﬁc immunity leading to lower CD4 counts and viral
persistence.
Hepatitis C virus is characterized by its ability to establish
chronic infection in the majority of those infected, and an
immunoregulatory role for Tregs in this process has been well
described. Chronic HCV patients have increased levels of CD4+
and Tr1 Tregs in peripheral blood which are thought to suppress
anti-viral T cell responses leading to viral persistence (Chang,
2007). Certain HCV epitope variants have been shown to induce
Tregs in HCV-infected patients (Cusick et al., 2011). Chronic
HCV patients have more serum IL-10 than those with resolved
infection, which is proposed to play a role in the induction of
CD4+FOXP3+ Tregs in chronic HCV infection (Macdonald et al.,
2002; Cusick et al., 2013); and CD49b, a marker for IL-10 pro-
ducing Tr1 Treg cells, is lower in those who respond to viral
therapy, thus suggesting a regulatory role for Tr1 Tregs too (Fabien
et al., 2014). Indoleamine 2,3-dioxygenase (IDO) production by
stimulated monocyte derived DCs was higher in HCV patients
compared to healthy controls, and these DCs were more able
to induce Tregs, suggesting a role for this Treg induction path-
way in chronic HCV (Higashitani et al., 2013). Expression of
the inhibitory signaling pathway molecule T cell immunoglobu-
lin and mucin-domain-protein-3 (Tim-3) is upregulated on both
Teff and CD4+CD25+FOXP3+ Tregs in chronic HCV, correlating
with increased Treg and decreased Teff proliferation, suggesting
that the Tim-3 pathway controls the Treg/Teff balance in chronic
HCV (Moorman et al., 2012). Viral persistence following acute
HCV infection is accompanied by increased plasma Galectin-9
(Gal-9) which is the ligand for Tim-3, alongside expanded Gal-9
expressing Tregs and increased expression of Tim-3 and CTLA-4
on HCV-speciﬁc CD8+ T cells (Kared et al., 2013). Thus high lev-
els of Tregs likely contribute to viral persistence in HCV infection,
and both FOXP3+ and Tr1 Tregs have been implicated. Mecha-
nisms of Treg induction in HCV may be multifactorial but include
HCV antigen driven induction, IL-10, IDO, Gal-9/Tim-3, and
CTLA-4.
ROLE OF Tregs IN CONTROLLING VACCINE
IMMUNOGENICITY
The role that Tregs play in controlling or limiting vaccine
immunogenicity remains to be fully determined. Given that Tregs
are induced by natural infections to regulate the inﬂammatory
response, it makes sense that Tregs would be induced as part of
the immune response to vaccination, particularly for live atten-
uated vaccines. One might predict that their induction would
play a beneﬁcial immunoregulatory role by preventing an over-
exuberant immune response to the vaccine. However,most studies
suggest that Tregs can interfere with the generation of vaccine-
induced immunity. Thus, depletion of Tregs pre-vaccination in
murine models has been shown to enhance immune responses
to some vaccines. In a DEREG mouse model, which allows for
in vivo depletion of Foxp3+ Treg cells at any point during an
immune response using diphtheria toxin (Lahl and Sparwasser,
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2011), Treg depletion led to an enhanced anti-tumor response
to vaccination against an established melanoma (Klages et al.,
2010). A more recent study showed that the short term deple-
tion of Tregs in DEREG mice greatly enhanced vaccine-induced
immunity against a solid tumor; increasing NK cells and CD8
T cell activation and IFN-γ production (Mattarollo et al., 2013).
Administration of vaccines with anti-CD25 monoclonal Ab has
been shown to induce more durable immunity in mice compared
to when the vaccine is administered alone, for both BCG and
hepatitis B vaccines, which has been attributed to a depletion
of CD25+ Tregs (Moore et al., 2005). Ho et al. (2010) showed
that antigen-speciﬁc Tregs induced by environmental mycobac-
teria suppress Th1 immune responses, thus compromising the
response to BCG vaccination in mice. They also showed a
correlation between the pre-existing Tregs and the subsequent
vaccine response. Murine studies of Parkinson’s disease have
shown that Tregs are induced by BCG vaccination (Lacan et al.,
2013).
It is difﬁcult to translate these studies into primates andhumans
since murine Tregs are not phenotypically identical, and in vivo
depletion of FOXP3+ Tregs in healthy humans presents logistic
and ethical challenges. An oral vaccine against simian immunode-
ﬁciency virus (SIV) based on a Lactobacillus commensal that favors
immune tolerance induction was used to induce T cell tolerance to
SIV antigens in macaques (Lu et al., 2012). The vaccine-induced
CD8+ Tregs that suppressedCD4+ Tcell activation and ex vivo SIV
replication, and provided sterile protection against an intrarectal
SIV challenge in 15 of 16 vaccinated macaques. This strategy is
thought to work because CD4+ T cell activation drives the initial
phase of viral replication, and provides the proof-of-concept that
an oral Treg inducing vaccine could prevent the establishment of
HIV infection.
Using a DC-based vaccine in HIV patients undergoing cART,
it was shown that depletion of the Tregs in vitro signiﬁcantly
enhanced the vaccine-induced anti-HIV-1-speciﬁc polyfunctional
T cell response, suggesting that Tregs can dampen vaccine-induced
immunity (Macatangay et al., 2010). This study also showed a
marked increase in the CD4+CD25hiFOXP3+ Treg numbers fol-
lowing vaccination, however, this increase did not correlate with
the effector CD8+ T cell vaccine-induced response. Increased
FOXP3 mRNA expression has been demonstrated in malaria vac-
cinated adults; however, the authors concluded that this might
be attributed to the participants being naturally exposed to the
malaria parasite rather than as a result of vaccination per se
(Mwacharo et al., 2009).
Very few studies have looked at the role that Tregs play in con-
trolling vaccine immunogenicity in infants. Our group found no
correlation between PPD-speciﬁc CD4+CD25+FOXP3+ Tregs or
CD4+IL-10+ Tregs, or PPD stimulated total IL-10 production
on the day of BCG vaccination of Gambian infants, and subse-
quent IFN-γ responses to PPD (Burl et al., 2010). No functional
Treg assays were conducted in this study. In another study we
found that placental associated malaria (PAM) infection is associ-
ated with increased malaria-speciﬁc CD4+CD25+FOXP3+ Tregs
(Flanagan et al., 2010) and that PAMalso correlates with decreased
immunogenicity of BCG vaccination as evidenced by poorer PPD
reactivity persisting to 1 year of age compared to PAM negative
children (Walther et al., 2012). Whether the Tregs are the cause of
this attenuation of BCG responses is not known.
TARGETING Tregs IN VIVO TO ENHANCE VACCINE
IMMUNOGENICITY
The cancer research ﬁeld has made considerable advances in dis-
secting the role that Tregs play in cancer progression and their
role in suppressing responses to cancer vaccines. Moreover, tri-
als conducted in animal models and humans have demonstrated
that certain drugs and immunotherapies can transiently decrease
Treg frequencies in vivo leading to improved anti-tumor Teff func-
tions, and in some cases reduced tumor load. Since Treg depletion
can enhance inﬂammation and autoimmunity then such tran-
sient depletion, as opposed to long term effects, is desirable.
In low doses, the agent cyclophosphamide transiently decreases
Treg frequencies while Teff functions are preserved, leading
to enhanced responses to vaccine antigens and improved vac-
cine immunogenicity in mouse and human cancer vaccine trials
(Barbon et al., 2010; Le and Jaffee, 2012). Anti-CD25 monoclonal
antibodies, which deplete Tregs in vivo, enhanced vaccine efﬁcacy
in mouse models of pancreatic carcinoma (Keenan et al., 2014)
and melanoma (Tan et al., 2013). Basiliximab and Daclizumab are
anti-human CD25 MAbs that cause both decreased number and
decreased function of Tregs by blocking IL-2 signaling (Goebel
et al., 2000; Kohm et al., 2006; Mitchell et al., 2011). Daclizumab
has beenused in several humanbreast cancer vaccine trials where it
depleted Tregs and improved effector responses, and furthermore
may reprogram naïve Tregs to become IFN-γ producers (Rech and
Vonderheide, 2009; Rech et al., 2012). The human monoclonal
antibody, Ipilimumab, inhibits Tregs by blocking CTLA-4; and
was approved by the FDA in 2011 for use in melanoma patients
(Peggs et al., 2009).
Certain innate agonists that are being used as vaccine adju-
vants preferentially expand Teff over Tregs, e.g., the TLR3 agonist
Poly(I:C) and the TLR9 agonist CpG-ODN; whereas others favor
Treg expansion, e.g., the TLR7 agonist imiquimod (Perret et al.,
2013). OX40 is part of the TNFR superfamily expressed by Teff
and Tregs, and the monoclonal antibody increases Teff function
while blocking Treg function. OX40 clones have been humanized
as potential agents to enhance the immunogenicity of vaccines
against infectious diseases (Voo et al., 2013).
An interesting approach is that of local depletion of Tregs at
the site of injection of a vaccine. Chemokine receptor 4 (CCR4)
antagonists can be used as vaccine adjuvants to target and decrease
local recruitment of CCR4+ Tregs in order to amplify vaccine
responses at the site of immunization (Bayry, 2014).
Therefore a number of agents that target Tregs are being used
experimentally in humans in order to enhance vaccine efﬁcacy.
Some of these are non-toxic and safe for use in humans, offering
the future prospect of using this approach to enhance immuno-
genicity of vaccines against infectious diseases including malaria,
HIV, and HCV.
TRIALS OF NOVEL VACCINES AGAINST MALARIA, HIV, AND
HCV IN INFANTS
Despite the multiple obstacles to successful infant vaccination dis-
cussed above, many vaccines are currently delivered in infancy
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with good immunogenicity, including the live BCG, measles and
yellow fever vaccines; and the inactivated diphtheria, tetanus, per-
tussis and hepatitis B vaccines, H. inﬂuenzae b, and pneumococcal
conjugate vaccine. The RTS,S/AS01 malaria vaccine is the most
advanced malaria vaccine in human clinical trials, having reached
phase III testing in children and infants, with potential licensure
in 2015. It reduced clinical and severe malaria by 56 and 47.3%
respectively in children aged 5–17 months (Bejon et al., 2008;
Olotu et al., 2011); but only 31.3 and 36.6% when administered
in three doses with routine Expanded Program on Immunization
(EPI) vaccines in the 6–12 week old age group (Rts et al., 2012).
Follow up of the 5–17 month old vaccinated group over a 4 year
period found protection waned to 16.8%; with waning greater
among those with higher malaria exposure suggesting that natu-
ral immunity to malaria contributes to the waning (Olotu et al.,
2013). Whether exposure induced Tregs play a role in this waning
has not been investigated.
Fowlpox and modiﬁed vaccinia Ankara (MVA) based malaria
vaccines have been tested in 1–6 year olds with no evidence
of protective efﬁcacy (Bejon et al., 2007). A blood stage vac-
cine FMP2.1/AS02A has been tested in Malian children aged
1–6 years with an efﬁcacy of <10% (Laurens et al., 2013). The
blood stage alum adjuvanted GMZ2 malaria vaccine elicited good
inhibitory antibody levels in pre-school children (Jepsen et al.,
2013). Prime-boost strategies based on chimp adenovirus vector
priming followed by MVA boosting are being tested in children
and infants in Africa, and while results of these trials are not yet
available the adult studies have shown unprecedented immuno-
genicity for malaria exposed populations (Ogwang et al., 2013)
and should stimulate good immunity in infants.
Only a few human HIV vaccine trials have been conducted
in healthy uninfected and HIV-exposed infants. Immunogenicity
was limited among healthy Gambian infants given a single dose
of MVA.HIVA, but this was not surprising given that MVA alone
is known to be poorly immunogenic (Afolabi et al., 2013). In a
Ugandan trial, infants were vaccinated at birth, 4, 8, and 12 weeks
of age with ALVAC-HIV vCP1521 (ALVAC) candidate HIV vac-
cine which induced low level CD4 and CD8 T cell responses at
24 months (Kaleebu et al., 2014).
The target population for HCV vaccines include intravenous
drug abusers and health care professionals. However, HCV
infection is common throughout the world and mother-to-child
transmission is well described (Yeung et al., 2001). Thus an infant
HCV vaccine would have its place, particularly in resource poor
settings where the anti-viral therapies available are currently not
affordable. Both therapeutic and prophylactic vaccines are being
developed, and several have now entered phase I/II human clin-
ical trials, mostly of therapeutic vaccines in chronically infected
cohorts. These include recombinant protein, peptide, DNA,
and vector-based vaccines aimed at producing robust anti-T cell
responses (Halliday et al., 2011). As far as we are aware no HCV
vaccine trials have been conducted in children.
FUTURE PROSPECTS
There is very little in the literature regarding the role of Tregs
in infants in general, and even less in respect to vaccine immuno-
genicity. The fact that functional Tregs are present in high numbers
in infancy and have potent suppressive activity, coupled with poor
immunological responses to some vaccines in this vulnerable age
group, supports a need to better understand the role they play in
controlling the response to childhood vaccines in particular. The
data available suggest that Tregs suppress immunity to vaccines,
and that they can also be induced by vaccination. We have shown
that malaria, HIV, and HCV all use Tregs to evade host immune
responses, therefore vaccine-induced Tregs would be predicted
to reduce the protective efﬁcacy of vaccines against these infec-
tions. A better understanding of the role that Tregs and other
immunoregulatory factors play in contributing to poor vaccine
immunogenicity in childhood would help with the design of bet-
ter vaccines. Studies in cancer patients have shown that transient
Treg inactivation or depletion is a viable approach to enhancing
vaccine efﬁcacy. A number of Treg modifying agents are available
for use in humans, therefore this approach is a very real prospect
for the future and may be particularly applicable to neonates and
infants.
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